AstraZeneca in-licenses Synairgen’s SNG001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma
12 June 2014 | By AstraZeneca
Phase IIa clinical study to commence in patients with severe asthma...
List view / Grid view
News
Brodalumab treatment improved clinical signs and symptoms in Phase 2 psoriatic arthritis study published in The New England Journal Of Medicine
12 June 2014 | By Amgen
Phase 3 program underway to further assess Brodalumab as potential treatment for people living with psoriatic arthritis...
Analysis: 6,000 new jobs in Novo Nordisk create a further 15,000 jobs in Denmark
11 June 2014 | By Novo Nordisk
Up to 2022, Novo Nordisk expects to hire 6,000 new employees in Denmark, half of whom will work within research and development...
Daiichi Sankyo awarded a Japan Science and Technology Agency “Newly extended Technology transfer Program” Grant
11 June 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that a R&D project for a novel, versatile vaccine adjuvant for the purpose of creating a novel vaccine has been awarded a “Newly extended Technology transfer Program”...
AbbVie presents results from large global study of patient attitudes and adherence across six chronic inflammatory diseases
11 June 2014 | By AbbVie
AbbVie announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases...
Pfizer announces over 10 abstracts for XELJANZ® (Tofacitinib Citrate) in rheumatoid arthritis to be presented at the European League Against Rheumatism Annual Meeting
11 June 2014 | By Pfizer
Additional data further characterizes the safety profile of XELJANZ...
GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD
11 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced positive results from two phase III studies, which showed that patients with chronic obstructive pulmonary disease who received the anticholinergic, Incruse™ Ellipta®...
AVERT trial demonstrates high rates of DAS-defined remission with Orencia® (abatacept) in combination with Methotrexate in adult patients with early rheumatoid arthritis
11 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced its first release of new data from a Phase IIIb RA trial showing that the T-cell co-stimulation modulator, Orencia...
Novo Nordisk to present 63 abstracts at 74th Annual American Diabetes Association Scientific Sessions in San Francisco, CA
10 June 2014 | By Novo Nordisk
Novo Nordisk, will unveil 63 abstracts containing safety and efficacy data from our class-leading portfolio of diabetes products at the 74th Annual Scientific Sessions of the American Diabetes Association...
Novartis Foundation for Sustainable Development to work with Netherlands Leprosy Relief to help reduce leprosy transmission
10 June 2014 | By Novartis
The Novartis Foundation for Sustainable Development and Netherlands Leprosy Relief announced their collaboration with national leprosy programs and other International Federation of Anti-Leprosy Associations...
Amgen appoints David W. Meline Executive Vice President and Chief Financial Officer
10 June 2014 | By Amgen
Amgen announced the appointment of David W. Meline as executive vice president and chief financial officer, effective July 21, 2014...
FDA approves expanded label for AZILECT® for treatment across all stages of Parkinson’s Disease
9 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced the U.S. Food and Drug Administration has expanded the indication for AZILECT® (rasagiline tablets)...
Merck to acquire Idenix
9 June 2014 | By Merck
Merck and Idenix Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash...
Giovanni Caforio, M.D., appointed Chief Operating Officer and elected to Board of Directors
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Giovanni Caforio, M.D., has been appointed chief operating officer and elected to Bristol-Myers Squibb’s Board of Directors, effective June 5, 2014. He will continue to report to Lamberto Andreotti, chief executive officer. In addition to his current responsibilities as chief commercial officer, Caforio…
First patient enrolled in new Phase 3 trial program investigating a once-daily dosing regimen of ISENTRESS® (raltegravir)
6 June 2014 | By Merck
Merck announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK...
